According to DelveInsight, the Diabetic Neuropathy pipeline includes over 20 key companies actively developing more than 25 therapeutic candidates for the treatment of diabetic neuropathy.
Diabetic Neuropathy Overview:
Diabetic neuropathy is a type of nerve damage that occurs in individuals with diabetes, particularly those with long-term poor blood sugar control. It mainly affects the peripheral nerves, which control sensation and movement in the limbs. Diabetic neuropathy can manifest in several forms, including peripheral neuropathy (impacting hands and feet), autonomic neuropathy (affecting internal organs), proximal neuropathy (causing pain in the thighs, hips, or buttocks), and focal neuropathy (targeting a specific nerve).
Symptoms vary depending on the type and extent of nerve damage. Peripheral neuropathy often presents as tingling, numbness, or pain in the extremities, which may worsen over time, potentially leading to loss of sensation and motor difficulties. Autonomic neuropathy can cause digestive issues, urinary problems, and cardiovascular complications. Proximal neuropathy typically causes pain in the thighs, hips, or buttocks, whereas focal neuropathy results in sudden, localized pain or weakness in a particular nerve.
Request for a detailed insights report on Diabetic Neuropathy pipeline insights
“Diabetic Neuropathy Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Diabetic Neuropathy Therapeutics Market.
Key Takeaways from the Diabetic Neuropathy Pipeline Report
-
DelveInsight’s Diabetic Neuropathy pipeline report highlights a vibrant landscape, featuring over 20 active companies developing more than 25 therapeutic candidates for the treatment of diabetic neuropathy.
-
Leading companies, including Serodus, Novartis, Curacle Co., Ltd, Sonnet BioTherapeutics, Teijin America, Shanghai Pharmaceuticals, ChemoCentryx, Roche, Cyclerion Therapeutics, Inversago Pharma, Sunshine Lake Pharma, Goldfinch Bio, Cosette Pharmaceuticals, Boehringer Ingelheim, Chinook Therapeutics, and others, are actively evaluating novel therapies to enhance the management of diabetic neuropathy.
-
Notable pipeline candidates in various stages of development include SER 150, LMB-763, CU01, among others.
-
In January 2024, Neuralace Medical received FDA clearance for Axon Therapy, a non-invasive magnetic peripheral nerve stimulation (mPNS) treatment for chronic painful diabetic neuropathy (PDN). This therapy delivers painless magnetic pulses in 13.5-minute sessions, representing a novel approach to pain management. Clinical evaluation through a double-blind, multicenter randomized controlled trial demonstrated a 72.3% responder rate and a 57.6% average reduction in pain scores at 30 days, with responder rates rising to 81.4% in the treatment group by 90 days.
Diabetic Neuropathy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Diabetic Neuropathy Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Neuropathy treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Diabetic Neuropathy market.
Download our free sample page report on Diabetic Neuropathy pipeline insights
Diabetic Neuropathy Emerging Drugs
-
SER 150: Serodus
-
LMB-763: Novartis
-
CU01: Curacle Co., Ltd
Diabetic Neuropathy Companies
Over 20 leading companies are actively working on therapies for diabetic neuropathy, with Serodus having a candidate in the most advanced stage, currently progressing through Phase II/III clinical trials.
DelveInsight’s report covers around 25+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Diabetic Neuropathy Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Diabetic Neuropathy Therapies and Key Companies: Diabetic Neuropathy Clinical Trials and advancements
Diabetic Neuropathy Pipeline Therapeutic Assessment
• Diabetic Neuropathy Assessment by Product Type
• Diabetic Neuropathy By Stage
• Diabetic Neuropathy Assessment by Route of Administration
• Diabetic Neuropathy Assessment by Molecule Type
Download Diabetic Neuropathy Sample report to know in detail about the Diabetic Neuropathy treatment market @ Diabetic Neuropathy Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Diabetic Neuropathy Current Treatment Patterns
4. Diabetic Neuropathy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Diabetic Neuropathy Late-Stage Products (Phase-III)
7. Diabetic Neuropathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Diabetic Neuropathy Discontinued Products
13. Diabetic Neuropathy Product Profiles
14. Diabetic Neuropathy Key Companies
15. Diabetic Neuropathy Key Products
16. Dormant and Discontinued Products
17. Diabetic Neuropathy Unmet Needs
18. Diabetic Neuropathy Future Perspectives
19. Diabetic Neuropathy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Diabetic Neuropathy Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/